Literature DB >> 11521224

Expression of cell cycle regulators p57(KIP2), cyclin D1, and cyclin E in epithelial ovarian tumors and survival.

E Rosenberg1, R I Demopoulos, A Zeleniuch-Jacquotte, H Yee, J Sorich, J L Speyer, E W Newcomb.   

Abstract

The search for new prognostic indicators is especially important in the diagnosis and treatment of ovarian cancer because clinicopathologic criteria currently used to predict survival are largely inadequate. We examined 2 groups of patients with epithelial ovarian cancer, 1 group of long-term survivors (>5 years), and 1 group of short-term survivors (<2 years) for levels of expression of the cell cycle regulators p57(KIP2), cyclin D1, and cyclin E and their relationship with survival. Our findings show that p57(KIP2) is not associated with prognosis, in contrast to p27(KIP1) expression, which is previously shown to be positively associated with long-term survival in univariate analysis (P =.001). Cyclin E expression, in contrast to cyclin D1 expression, is marginally associated with short-term survival in univariate analysis for a group of 53 women. Among the short-term survivors, 15 (65%) of 23 were positive for cyclin E expression, compared with only 11 (37%) of 30 long-term survivors (P = 0.054). This association remained significant (P =.04) in a logistic regression analysis adjusted simultaneously for performance status and extent of residual disease, the 2 strongest predictors of survival in our study. We also found a significant difference in the frequency of the cyclin E staining pattern between nonserous and serous ovarian tumor subtypes (P =.0002). Immunostaining for levels of cyclin E and p27(KIP1) expression may have potential as prognostic markers in the management of ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11521224     DOI: 10.1053/hupa.2001.26462

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  17 in total

1.  Lidocaine inhibits the proliferation of lung cancer by regulating the expression of GOLT1A.

Authors:  Lei Zhang; Rong Hu; Yanyong Cheng; Xiaoyang Wu; Siwei Xi; Yu Sun; Hong Jiang
Journal:  Cell Prolif       Date:  2017-07-24       Impact factor: 6.831

2.  MicroRNA-30c-2-3p negatively regulates NF-κB signaling and cell cycle progression through downregulation of TRADD and CCNE1 in breast cancer.

Authors:  Kirti Shukla; Ashwini Kumar Sharma; Aoife Ward; Rainer Will; Thomas Hielscher; Aleksandra Balwierz; Christian Breunig; Ewald Münstermann; Rainer König; Ioanna Keklikoglou; Stefan Wiemann
Journal:  Mol Oncol       Date:  2015-02-10       Impact factor: 6.603

3.  MiR-221 and MiR-222 alterations in sporadic ovarian carcinoma: Relationship to CDKN1B, CDKNIC and overall survival.

Authors:  Kaitlyn Wurz; Rochelle L Garcia; Barbara A Goff; Patrick S Mitchell; Jun Haeng Lee; Muneesh Tewari; Elizabeth M Swisher
Journal:  Genes Chromosomes Cancer       Date:  2010-07       Impact factor: 5.006

4.  Expression of cell cycle regulator p57kip2, cyclinE protein and proliferating cell nuclear antigen in human pancreatic cancer: an immunohistochemical study.

Authors:  Hui Yue; Hui-Yong Jiang
Journal:  World J Gastroenterol       Date:  2005-08-28       Impact factor: 5.742

5.  Expression of p57(kip2) and its relationship with clinicopathology, PCNA and p53 in primary hepatocellular carcinoma.

Authors:  Ke-Jun Nan; Hui Guo; Zhi-Ping Ruan; Zhao Jing; Shaan-Xi Liu
Journal:  World J Gastroenterol       Date:  2005-02-28       Impact factor: 5.742

6.  Expression of p57kip2, Rb protein and PCNA and their relationships with clinicopathology in human pancreatic cancer.

Authors:  Hui Yue; Yan-Li Na; Xin-Li Feng; Shu-Ren Ma; Fu-Lin Song; Bo Yang
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

7.  Inducible expression of p57KIP2 inhibits glioma cell motility and invasion.

Authors:  K Sakai; A Peraud; T Mainprize; J Nakayama; A Tsugu; K Hongo; S Kobayashi; James T Rutka
Journal:  J Neurooncol       Date:  2004-07       Impact factor: 4.130

8.  The cyclin-dependent kinase inhibitor p57(Kip2) is epigenetically regulated in carboplatin resistance and results in collateral sensitivity to the CDK inhibitor seliciclib in ovarian cancer.

Authors:  H M Coley; N A M Safuwan; P Chivers; E Papacharalbous; T Giannopoulos; S Butler-Manuel; K Madhuri; D P Lovell; T Crook
Journal:  Br J Cancer       Date:  2012-01-10       Impact factor: 7.640

9.  Relevance of immunohistochemical expression of p57kip2 in epithelial ovarian carcinoma- A systematic literature review.

Authors:  Thumuluru Kavitha Madhuri; Anil Tailor; Ben Haagsma; Helen Coley; Simon Butler-Manuel
Journal:  J Ovarian Res       Date:  2012-12-21       Impact factor: 4.234

10.  Expression of p15INK⁴b and p57KIP² and relationship with clinicopathological features and prognosis in patients with vulvar squamous cell carcinoma.

Authors:  Ruth Holm; Mette Førsund; Mai T Nguyen; Jahn M Nesland; Claes G Trope
Journal:  PLoS One       Date:  2013-04-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.